Meeting Future Global Challenges: Case-Based Presentations in the Management of NSCLC - a podcast by ReachMD

CME credits: 0.25

Valid until: 16-06-2022

Claim your CME credit at https://reachmd.com/programs/cme/meeting-future-global-challenges-case-based-presentations-management-nsclc/12600/

For the 3% to 4% of patients with non-small cell lung cancer (NSCLC) who harbor a MET exon 14 skipping mutation, the prognosis is grave. MET gene dysregulation may also play a role in the emergence of resistance to EGFR TKI therapy in patients with EGFR-mutated NSCLC, further complicating treatment. Join our case discussion as Dr. Paul Paik and Dr. Josh Sabari highlight the importance of identifying MET gene aberrations in patients with NSCLC.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD